Q-omics provides the consensus-scored MIR1295A profile across patient tissues and cancer cell-line models. MIR1295A expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR1295A is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR1295A RNA expression shows 8,703 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight THCA, BRCA, and COAD as cancer lineages where MIR1295A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1295A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1295A survival associations across molecular data types. MIR1295A RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1295A RNA expression–survival associations across cancer types. High MIR1295A expression shows unfavorable associations in THCA, CESC and DLBC, but favorable associations in ESCA, LUAD and LIHC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR1295A RNA expression.
This table summarizes MIR1295A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1295A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1295A shows lower tumor expression in BRCA, CHOL and LUSC and higher tumor expression in LIHC. The BRCA box plot shows higher MIR1295A RNA expression in normal versus tumor tissue (log2 FC = −0.388, t-test p < 0.001).
This table shows molecular features associated with MIR1295A in patient tissues and cancer cell lines. In patient samples, MIR1295A shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
